MEASUREMENT OF THE CLASS-III ANTIDYSRHYTHMIC DRUG, UK-68,798, IN PLASMA BY RADIOIMMUNOASSAY

被引:26
|
作者
WALKER, DK
AHERNE, GW
ARROWSMITH, JE
CROSS, PE
KAYE, B
SMITH, DA
STOPHER, DA
WILD, W
机构
[1] GUILDHAY ANTISERA LTD,RIVERSIDE BUSINESS CTR,UNIT 6,GUILDFORD GU1 4UG,SURREY,ENGLAND
[2] PFIZER LTD,CENT RES,DEPT DISCOVERY CHEM,SANDWICH CT13 9NJ,KENT,ENGLAND
关键词
CLASS-III ANTIDYSRHYTHMIC DRUG,UK-68,798; RADIOIMMUNOASSAY; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY;
D O I
10.1016/0731-7085(91)80137-X
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A sensitive radioimmunoassay (RIA) for the specific determination of 1-(4-methanesulphonamidophenoxy)-2-[N-(4-methanesulphonamido-phenethyl)-N-methylamino]ethane (UK-68,798), a novel class III antidysrhythmic agent, in human plasma is described. Specific antisera were raised in sheep using desmesyl-UK-68, 798-succinate-ovalbumin conjugate as the antigenic hapten carrier protein. The antisera produced exhibited high specificity for UK-68, 798 compared with known metabolites from animals, other antidysrhythmic agents and co-administered drugs. Good correlation was found in a comparison of the RIA method with a high-performance liquid chromatography (HPLC) method (r = 0.997) and a 10-fold lower limit of determination was observed for the RIA method compared with the HPLC method (0.05 and 0.5 ng ml-1, respectively). The RIA method was applied to the analysis of UK-68, 798 in plasma obtained from human volunteers receiving the compound.
引用
收藏
页码:141 / 149
页数:9
相关论文
共 50 条
  • [31] CLINICAL-PHARMACOLOGY OF ORAL DOFETILIDE (D), A CLASS-III ANTIARRHYTHMIC DRUG
    HARRON, DWG
    THAM, TCK
    MACLENNAN, BA
    RASMUSSEN, HS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 174 - 174
  • [32] TORSADES-DE-POINTES WITH ALMOKALANT, A NEW CLASS-III ANTIARRHYTHMIC DRUG
    WIESFELD, ACP
    CRIJNS, HJGM
    BERGSTRAND, RH
    ALMGREN, O
    HILLEGE, HL
    LIE, KI
    AMERICAN HEART JOURNAL, 1993, 126 (04) : 1008 - 1011
  • [33] THE CLINICAL ELECTROPHYSIOLOGICAL EFFECTS OF D-SOTALOL - A NEW CLASS-III ANTIARRHYTHMIC DRUG
    ROWLAND, E
    PERRINS, EJ
    DONALDSON, RM
    RICKARDS, AF
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1985, 5 (02) : 498 - 498
  • [34] THE CLINICAL ELECTROPHYSIOLOGICAL EFFECTS OF D-SOTALOL - A NEW CLASS-III ANTIARRHYTHMIC DRUG
    DONALDSON, RM
    ROWLAND, E
    TAGGART, P
    SUTTON, P
    RICKARDS, A
    CLINICAL SCIENCE, 1985, 68 : P30 - P30
  • [35] THE UTILITY OF SERUM DRUG LEVEL MONITORING DURING THERAPY WITH CLASS-III ANTIARRHYTHMIC AGENTS
    FOLLATH, F
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 20 : S41 - S43
  • [36] HOW TO EVALUATE CLASS-III ANTIARRHYTHMIC DRUG EFFICACY CLINICALLY - THE BENEFITS AND SHORTCOMINGS OF THE INVASIVE APPROACH
    BORGGREFE, M
    HAVERKAMP, W
    SHENASA, M
    HINDRICKS, G
    BREITHARDT, G
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 20 : S32 - S40
  • [37] CLINICAL INVESTIGATION OF A NEW CLASS-III ANTIARRHYTHMIC DRUG NIBENTAN .1. TOLERABILITY STUDY
    RUDA, MY
    MERKULOVA, IN
    TARARAK, AE
    BLOKHIN, AB
    GOLITSIN, SP
    ROSENSHTRAUKH, LV
    CHAZOV, EI
    KARDIOLOGIYA, 1995, 35 (09) : 4 - 15
  • [38] HOW TO EVALUATE CLASS-III ANTIARRHYTHMIC DRUG EFFICACY CLINICALLY - THE BENEFITS AND SHORTCOMINGS OF THE NONINVASIVE APPROACH
    ANDRESEN, D
    BEHRENS, S
    STERN, R
    BRUGGEMANN, T
    SCHRODER, R
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 20 : S28 - S31
  • [39] BLOCKADE OF DELAYED RECTIFIER K+ CURRENTS IN NEUROBLASTOMA X GLIOMA HYBRID (NG-108-15) CELLS BY CLOFILIUM, A CLASS-III ANTIDYSRHYTHMIC AGENT
    REEVE, HL
    PEERS, C
    BRITISH JOURNAL OF PHARMACOLOGY, 1992, 105 (02) : 458 - 462
  • [40] CLINICAL ELECTROPHYSIOLOGY OF INTRAVENOUS SOTALOL, A BETA-BLOCKING DRUG WITH CLASS-III ANTIARRHYTHMIC PROPERTIES
    TOUBOUL, P
    ATALLAH, G
    KIRKORIAN, G
    LAMAUD, M
    MOLEUR, P
    AMERICAN HEART JOURNAL, 1984, 107 (05) : 888 - 895